SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001628280-22-010129
Filing Date
2022-04-25
Accepted
2022-04-25 16:34:43
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A defa14a-2022.htm DEFA14A 15011
2 vandapharmaceuticalsinc_vs.jpg GRAPHIC 360127
3 vandapharmaceuticalsinc_vsa.jpg GRAPHIC 490282
  Complete submission text file 0001628280-22-010129.txt   1186949
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-34186 | Film No.: 22850129
SIC: 2834 Pharmaceutical Preparations